Cushing syndrome in a 55-year-old case of small-cell lung cancer

Message:
Article Type:
Review Article (دارای رتبه معتبر)
Abstract:

Lung cancer is the deadliest type of cancer in the world, and small cell lung cancer (SCLC) is one of the most fatal types of relevant tumors. The aim of this report was to describe the status of a patient presenting with progressive weakness, who did not have a previous medical history. Clinical examination revealed bilateral edema of the lower limbs. Lab results exhibited severe hypokalemia and metabolic alkalosis. physical examination showed elevated blood pressure. Imaging revealed a large mass with necrosis. Bronchoscopy was done and biopsy pathology showed SCLC. The patient underwent chemotherapy with cisplatin and etoposide. Following SCLC, the patient developed a type of paraneoplastic syndrome called Cushing syndrome. He experienced a severe decrease in saturation in the second session of chemotherapy and eventually died. With respect to the fact that most paraneoplastic syndromes are associated with poor response to treatment, high clinical suspicion is essential for the rapid diagnosis of these syndromes to improve outcomes.

Language:
English
Published:
Basic and Clinical Cancer Research, Volume:14 Issue: 3, Summer 2022
Pages:
151 to 154
magiran.com/p2631248  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!